FDA renews leadership search; lung cancer drug rejected by agency
Published 7 h ago2 sourcesEvidence: Reported
The FDA approved Sanofi's venglustat (Infilbray), the first oral therapy targeting CNS manifestations of the neurological variant of Gaucher disease. This is a regulatory milestone for a rare-disease indication, but commercial impact is limited by the small patient population. The approval may bolster Sanofi's rare-disease portfolio but is not a macro market signal.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 7 h ago2 sourcesEvidence: Reported
Published 4 h ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 7 h ago2 sourcesEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 16 h ago1 sourceEvidence: Reported
Published 2 d ago3 sourcesEvidence: Reported
Published 6 h ago2 sourcesEvidence: Reported